Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.49 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | PKM | P14618 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19987536 | 0.88 | HSD17B10 (0.51) | HSD17B10TRPV1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL20306361 | 0.85 | HSD17B10 (0.43) | HSD17B10TRPV1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL13930929 | 0.81 | HSD17B10 (0.51) | HSD17B10TRPV1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL84370 | 0.80 | TRPV1 (0.59) | HSD17B10TRPV1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL25057020 | 0.78 | POLB (0.55) | HSD17B10TRPV1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL6088891 | 0.77 | HSD17B10 (0.54) | HSD17B10TRPV1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL9853857 | 0.76 | POLB (0.56) | HSD17B10TRPV1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL19987534 | 0.75 | SMN1; SMN2 (0.51) | HSD17B10TRPV1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL24037602 | 0.74 | ALDH1A1 (0.38) | HSD17B10SMN1; SMN2ALDH1A1ESR1NPSR1 | |
| SCHEMBL25056938 | 0.73 | POLB (0.54) | HSD17B10TRPV1SMN1; SMN2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210154308-A1 | POLYMERIC DRUG CONJUGATES WITH TETHER GROUPS FOR CONTROLLED DRUG DELIVERY | NOVARTIS AG (CH) | 2021-05-27 | — | — | US | disclosed |
| US-10399933-B2 | Inhibitors of indoleamine-2,3-dioxygenase for the treatment of cancer | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-09-03 | — | — | US | disclosed |
| US-20180072660-A1 | INHIBITORS OF INDOLEAMINE-2,3-DIOXYGENASE FOR THE TREATMENT OF CANCER | BRISTOL MYERS SQUIBB CO (US) | 2018-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210154308-A1 | POLYMERIC DRUG CONJUGATES WITH TETHER GROUPS FOR CONTROLLED DRUG DELIVERY | CD44, MSN, ABCB1 | HSD17B10 1176/4885TRPV1 4862/4885SMN1; SMN2 1975/4885 |
| US-20180072660-A1 | INHIBITORS OF INDOLEAMINE-2,3-DIOXYGENASE FOR THE TREATMENT OF CANCER | IDO1, IDO2, INMT | HSD17B10 844/4885TRPV1 2719/4885SMN1; SMN2 4521/4885 |
| US-10399933-B2 | Inhibitors of indoleamine-2,3-dioxygenase for the treatment of cancer | IDO1, IDO2, INMT | HSD17B10 844/4885TRPV1 2719/4885SMN1; SMN2 4521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.